含溴结构域蛋白4（BRD4）是一种重要的表观遗传学读者，与多种疾病的发病机制和发展密切相关，包括各种癌症、炎症和传染病等。用小分子靶向抑制 BRD4 或消除蛋白质代表了一种有前途的治疗策略，特别是对于癌症治疗。总结了专利 BRD4 降解剂的最新进展。还讨论了开发新型有效和选择性 BRD4 降解剂的挑战、机遇和未来方向。通过SciFinder和Cortellis Drug Discovery Intelligence数据库检索了BRD4降解剂的专利。由于其独特的蛋白质降解而非蛋白质抑制机制，BRD4降解剂表现出优于BRD4抑制剂的功效和选择性。令人兴奋的是，RNK05047 目前正处于 I/II 期临床试验，表明选择性 BRD4 蛋白降解可能提供一种可行的治疗策略，特别是对于癌症。用小分子 BRD4 降解剂靶向 BRD4 提供了一种有前景的方法，有可能克服治疗各种 BRD4 相关疾病的耐药性。

Bromodomain-containing protein 4 (BRD4), an important epigenetic reader, is closely associated with the pathogenesis and development of many diseases, including various cancers, inflammation, and infectious diseases. Targeting BRD4 inhibition or protein elimination with small molecules represents a promising therapeutic strategy, particularly for cancer therapy.The recent advances of patented BRD4 degraders were summarized. The challenges, opportunities, and future directions for developing novel potent and selective BRD4 degraders are also discussed. The patents of BRD4 degraders were searched with SciFinder and Cortellis Drug Discovery Intelligence database.BRD4 degraders exhibit superior efficacy and selectivity to BRD4 inhibitors, given their unique mechanism of protein degradation instead of protein inhibition. Excitingly, RNK05047 is now in phase I/II clinical trials, indicating that selective BRD4 protein degradation may offer a viable therapeutic strategy, particularly for cancer. Targeting BRD4 with small molecule BRD4 degraders provides a promising approach with the potential to overcome therapeutic resistance for treating various BRD4-associated diseases.